Regional Lung Imaging Using Hyperpolarized Xenon Gas

Status Completed

Clinical Trial Summary

The investigators aim to use hyperpolarized xenon gas magnetic resonance imaging (MRI) and computed tomography to develop a new technique capable of objectively and quantitatively describing regional and structural lung abnormality. Since this is a relatively novel technique, the investigators first need to acquire imaging and clinical data from a group of participants with normal lungs. The investigators hope to generate an "atlas" of normality, which will form the foundation of future studies to compare with patients suffering from chronic respiratory disease. The investigators also aim to validate the new technique in terms of intra-subject reproducibility.

Clinical Trial Description

Currently, the gold standard for assessment of lung function in chronic respiratory disease is spirometry. This is combined with anatomical imaging (chest x-ray and computed tomography) for structural assessment. Spirometry only measures global lung function. It provides no information regarding the different regions of the lung or about the supporting "framework" of the lung itself, the parenchyma. In addition, changes in lung function as measured with spirometric indices do not correlate coherently with the symptoms experienced by patients, nor reflect their decline in health. This weak relationship is probably because the lung is a complex regional organ where localized disturbances of a variety of factors including gas flow (ventilation), blood flow (perfusion) and gas transfer all combine to impair respiratory function. MRI has the advantage of being an imaging technique free from ionizing radiation making it safe and practical for diseases such as asthma and obstructive lung disease where repeated follow-up scans are necessary. Hyperpolarized xenon, in the doses given for imaging has been shown to be safe. Conventional MRI has limited use in respiratory disease, because the lung is largely composed of air spaces that do not generate an MR signal. Hyperpolarized noble gases can resolve this problem. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02112929
Study type	Interventional
Source	Oxford University Hospitals NHS Trust
Contact
Status	Completed
Phase	Phase 1
Start date	April 2012
Completion date	September 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02253667` - Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients	N/A
Completed	`NCT02217423` - Abdominal Circumference and Cardiorespiratory Repercussions in Patients Submitted to Physical Therapy	N/A
Completed	`NCT02345135` - Susceptibility to Infections in Ataxia Telangiectasia	N/A
Completed	`NCT01679301` - Evaluation of Sleep Mode Within the Respironics SimplyGo Portable Oxygen Concentrator	N/A
Terminated	`NCT00966823` - Fetal Tracheal Balloon Study in Diaphragmatic Hernia	Phase 2
Completed	`NCT00139152` - Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair	Phase 4
Completed	`NCT00052052` - An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)	Phase 2
Completed	`NCT00013949` - Cardiovascular Vulnerability to Particulate Exposure	N/A
Recruiting	`NCT02963467` - Effect of Smoking on Ventilation-Perfusion Ratio	N/A
Recruiting	`NCT02965300` - The Value of VOCs Analysis in Exhaled Breath for Pulmonary Benign and Malignant Lesion Diagnosis	N/A
Enrolling by invitation	`NCT02946658` - Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders	Phase 1/Phase 2
Recruiting	`NCT02913365` - Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis	N/A
Completed	`NCT01735526` - Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide After Hematopoietic Stem-cell Transplantation	N/A
Completed	`NCT01952002` - Clinical Safety for the Inspiratory Muscle Training	N/A
Recruiting	`NCT01450644` - Evaluation of the Hospital2Home Palliative Care Service for Patients With Advanced Progressive Lung Disease	Phase 2
Completed	`NCT01215279` - AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)	Phase 2
Completed	`NCT01153321` - Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)	Phase 2
Completed	`NCT00837681` - Pulmonary Complications of Hematopoietic Stem Cell Transplantation	N/A
Completed	`NCT02055222` - Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
Completed	`NCT01222442` - To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.